AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05497869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active release group
Description: Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
Study NCT05497869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
Study NCT05126602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10000 IU
Description: Tablet of 5000 IU of vitamin D3 given twice daily
Study NCT05126602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 1000 IU
Description: Tablet of 1000 IU of vitamin D3 given once daily
Study NCT05978661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKC288
Description: Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
Study NCT06369129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital floor reconstruction with Patient Specific Zirconia Implant
Description: Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
Study NCT06369129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital floor reconstruction with Patient Specific Titanium Implant
Description: Orbital floor reconstruction with Patient Specific Titanium Implant will be done
Study NCT05792046 — intervention group
Intervention type: DEVICE
Intervention: Visual field
Description: test for detecting loss in visual function
Study NCT06231082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group one - percutaneous (P)
Description: Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
Study NCT06231082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group two - EUS FNB (E)
Description: EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique.
Study NCT06161272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: single
Study NCT06161272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: combination
Study NCT06562751 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Online questionnaire designed by the investigatory team.
Study NCT06562751 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Online focus group
Study NCT06562751 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Online semi-structured interview
Study NCT06562751 — intervention group
Intervention type: OTHER
Intervention: Workshop
Description: Online and face to face co-production workshops
Study NCT04872400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
Study NCT06054893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm
Study NCT04872400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
Study NCT04287608 — intervention group
Intervention type: DRUG
Intervention: dupilumab
Description: No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
Study NCT05491512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18 F-FMISO PET/CT
Description: The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
Study NCT05491512 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
Study NCT05491512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
Study NCT05491512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)
Study NCT05491512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
Study NCT05472649 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gene-Modified Cell Therapy
Description: No investigational cell product will be administered
Study NCT04934462 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: physiotherapy
Description: Six months physiotherapy aimed at hip stability.
Study NCT04934462 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthroscopy
Description: Arthroscopic plication of hip joint capsule.
Study NCT06593327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Prevention Strategy
Description: Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
Study NCT06651658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleural embolisation
Description: Administration of pleural blood patch with tandem needle technique
Study NCT06650696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCE promotion
Description: The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
Study NCT06650696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study NCT06650696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
Study NCT06650696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotiaonl skill enhancement
Description: This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
Study NCT06601907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alivis
Description: alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
Study NCT06610357 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: 42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
Study NCT06610799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
Study NCT05707182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3
Description: 18F-rhPSMA-7.3 PET/MR
Study NCT05788653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thiele Massage
Description: Transvaginal Massage
Study NCT05788653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Friction Massage
Description: Transvaginal Massage
Study NCT06368921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRT106
Description: intratumoral injection
Study NCT04934475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
Study NCT04934475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: ASCT for ams B, C and D during consolidation
Study NCT06087406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imvotamab
Description: Administered intravenously
Study NCT06087406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride administered intravenously
Study NCT06142383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: S.C. Injection
Study NCT06142383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 Low dose
Description: S.C. Injection
Study NCT06142383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 Medium Dose
Description: S.C. Injection
Study NCT06142383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XXB750 High Dose
Description: S.C. Injection
Study NCT06142383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/valsartan
Description: Tablet
Study NCT06405139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
Description: Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
Study NCT05588778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ¡En Forma y Fuerte! @home/en casa
Description: The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
Study NCT04421573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCPHD with D5W
Description: D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
Study NCT04421573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Waiting period with usual care
Description: Same as previous group description
Study NCT05553496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
Study NCT05553496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
Study NCT04805385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: Each PS128 capsule contained >1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
Study NCT04805385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS128
Description: Each PS128 capsule contained >1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
Study NCT06202534 — intervention group
Intervention type: OTHER
Description: radiotherapy
Study NCT05911919 — intervention group
Intervention type: DEVICE
Intervention: brainQuant module of brainTale-care platform
Description: brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
Study NCT06019507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product
Study NCT06019507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Regimen
Study NCT06019507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Immunosuppression Therapy
Study NCT06019507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppression Therapy
Study NCT06019507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Immunosuppression Therapy
Study NCT06654791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C] SIM0270 Oral Preparation
Description: Use according to the prescribed protocol
Study NCT04797481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
Study NCT04797481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-managed exercise
Description: Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
Study NCT04981067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maintain the concentration of ropivacaine as same as those used in the previous participant
Description: Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
Study NCT04981067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant
Description: Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
Study NCT04981067 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant
Description: Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
Study NCT06589661 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
Study NCT06605456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation with postural education
Description: Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles. Then, resisted scapular posterior depression PNF exercise also employed.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration.
Study NCT06605456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neck muscle stretching and strengthening exercises
Description: Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration.
Study NCT06597760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
Study NCT06597760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.